Trump signals tariff plans, Fed chair candidates, China deal progress
LONDON - Roquefort Therapeutics plc (LSE:ROQ) announced Thursday that all resolutions proposed at its Annual General Meeting were approved by shareholders.
The biotech company, which focuses on developing immunology and oncology medicines, reported that shareholders voted overwhelmingly in favor of all nine resolutions presented at the meeting. According to the poll results, support for the resolutions ranged from 96.56% to 98.73%.
The highest approval rate of 98.73% was recorded for resolutions 1, 6, and 7, while resolution 9 received the lowest approval at 96.56%.
Approximately 10.3% of the company’s voting capital participated in the AGM voting process. As of June 24, 2025, the deadline for proxy votes, Roquefort Therapeutics had 157,444,030 ordinary shares in issue.
The company conducted the vote via poll, with vote tallies showing between 15.6 million and 16 million shares cast in favor of each resolution, while votes against ranged from approximately 205,000 to 558,000 shares.
Roquefort Therapeutics is listed on the Main Market of the London Stock Exchange (LON:LSEG) and describes itself as focused on developing first in class medicines in the immunology and oncology markets.
The information in this article is based on a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.